Analysis of the Thymidylate Synthase Gene Structure in Colorectal Cancer Patients and Its Possible Relation with the 5‐Fluorouracil Drug Response

Calascibetta, A; Contino, Flavia; Feo, Salvatore; Gulotta, Gaspare; Cajozzo, Massimo; Antona, A; Sanguedolce, Giorgio; Sanguedolce, R

doi:10.4061/2010/306754

Cited by 11 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While many studies have reported a correlation between high DPD expression levels and chemoresistance or poor survival rate, the prognostic value of DPD expression is still controversial in induction chemotherapy with 5-FU/cisplatin. Further studies that assess DPD levels using an enzyme assay or that examine the modification of molecular structures caused by mutations, as a previous study indicated (14), may clarify a potential role for DPD as a marker for response to induction chemotherapy with 5-FU/cisplatin.…”

Section: Discussionmentioning

confidence: 94%

Predictive biomarkers for combined chemotherapy with 5‑fluorouracil and cisplatin in oro‑ and hypopharyngeal cancers

et al. 2017

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 94%

Predictive biomarkers for combined chemotherapy with 5‑fluorouracil and cisplatin in oro‑ and hypopharyngeal cancers

et al. 2017

View full text Add to dashboard Cite

“…These genotypic effects may contribute to individual susceptibility to BC [11,12], and have been related to pharmacogenetic variation in chemotherapy treatments [14,15]. …”

Section: Introductionmentioning

confidence: 99%

Thymidylate synthase gene (TYMS) polymorphisms in sporadic and hereditary breast cancer

2012

View full text Add to dashboard Cite

BackgroundBreast cancer (BC) is a genetic disorder characterized by growth and proliferation of breast cells in a disorderly. In Brazil, there are approximately 49.240 new cases of BC, every year. The BC etiology is still poorly understood. The BC can be sporadic (SBC) or hereditary (HBC). Recent studies have correlated gene polymorphisms with the BC, such as alterations in thymidylate synthase gene (TYMS), which are used to improve diagnosis and prevention of the disease. Polymorphisms in the TYMS gene 5’-UTR region, usually present reps double (2R) and/or triple (3R). Studies have shown that homozygous 3R/3R is overexpressed compared with 2R/2R genotype, and these polymorphic variations may contribute to individual susceptibility to the development of BC. In this context, the objective of this study was to evaluate the frequency of the TYMS 2R and 3R polymorphisms, comparing genotypic and allelic distribution with SBC and HBC patients.MethodsIn this study we included a total of 204 subjects, 70 with BC (33 with SBC, and 37 with HBC) and 134 healthy subjects (controls). The Polymerase Chain Reaction was the method used.ResultsResults demonstrated a high frequency of the 3R allele at BC, SBC, and HBC groups. The frequency of genotype 2R/3R was significantly higher in BC group. This work showed association between the 2R/3R variants (OR = 4.14, CI95% = 1.77-9.71) in the development of SBC, and 2R/2R (OR = 0.233, CI95% = 1.63-7.65) and 2R/3R (OR = 3.53, CI95% = 0.06-0.81) for developing HBC. To BC, there was association with the genotype 2R/3R (OR: 3.79, CI95% = 2.03-7.08).ConclusionOur results show relation to the development of BC in association with the analyzed polymorphisms.

show abstract

“…Elevated intracellular TS levels have been implicated in emerging resistance to fluoropyrimidines and other TS inhibitors due to the increase in transcription and translation roles of TS. Therefore, high TS expression in early-stage CRC patients is correlated to a poorer overall survival in both chemotherapy-treated and chemotherapy-untreated patients following surgery [31].…”

Section: • Positive Marginsmentioning

confidence: 99%

Treatment Strategies in Colorectal Cancer

Daaboul¹,

El‐Sibai²

2018

Colorectal Cancer - Diagnosis, Screening and Management

View full text Add to dashboard Cite

Colorectal cancer is known to be one of the most commonly diagnosed cancers worldwide. It maintains a high mortality rate despite the newest methodological therapeutic approaches adopted in various academic establishments. The treatment modalities in colorectal cancer follow the degree of disease progression based on staging information. Earliest the cancer is diagnosed, the highest the possibility to be cured. Different strategies are being involved in treating colorectal cancer, starting from simple endoscopic polypectomy to remove a potential malignant polyp, to wider surgical intervention to get rid of a primary unmetastasized tumor, to other concomitant radio-chemotherapy combinations to reduce a bulky tumor rendering it operable, ending in more sophisticated chemotherapeutical regimens combined with targeted drugs to shrink the metastatic lesions and prolong survival rate. Different new treatments are being investigated with a sole aim to preserve the patient's quality of life and extend life span.

show abstract

Analysis of the Thymidylate Synthase Gene Structure in Colorectal Cancer Patients and Its Possible Relation with the 5‐Fluorouracil Drug Response

Cited by 11 publications

References 11 publications

Predictive biomarkers for combined chemotherapy with 5‑fluorouracil and cisplatin in oro‑ and hypopharyngeal cancers

Predictive biomarkers for combined chemotherapy with 5‑fluorouracil and cisplatin in oro‑ and hypopharyngeal cancers

Thymidylate synthase gene (TYMS) polymorphisms in sporadic and hereditary breast cancer

Treatment Strategies in Colorectal Cancer

Contact Info

Product

Resources

About